6 September 2010, 2:33 pm
Data Presented at ASRS Confirm Previous Phase III Findings and Microplasmina TMs Potential to Transform the Treatment of Retinal Disorders Leuven, Belgium a '-a ' ThromboGenics NV , a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second ...... Read More »